Propranolol: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and PBAC (Australia), among others, recommended or restricted propranolol, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 12.6 years separate the first record, 5 Dec 2007 at HAS (France), from the most recent, 9 Jul 2020 at HAS (France).
No assessment is on file from SMC (Scotland) and CIPM (Spain), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
2 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess propranolol, on 5 Dec 2007; PBAC (Australia) did not open a file until 2015 — a wide spread of 7.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 8 years in total.
3 of the 6 agencies here assessed propranolol more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for propranolol.
The full ledger for propranolol reads 10 recommended, 2 other, 1 not recommended and 1 advice.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 9 Jul 2020 | Listing renewal (Transparency Committee) | SMR substantial · ASMR III | source |
| PBAC (Australia) | 2015 | Infantile hemangioma | The PBAC rejected the proposed price for Hemangiol and reaffirmed its decision in March 20… | source |
| TLV (Sweden) | 20 Feb 2015 | Hemangiol ingår i högkostnadsskyddet | general subsidy | source |
| G-BA (Germany) | 19 Feb 2015 | Hemangiol — benefit assessment §35a | added benefit: major (indication) | source |
| AWMSG (Wales) | 14 Aug 2014 | for the treatment of proliferating infantile haemangioma requiring systemic therapy: life- or function-threatening haema… | not endorsed (non-submission) | source |
9 further decisions for propranolol, across 4 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- timolol — same ATC class C07A — Beta blockers
- timolol / travoprost — same ATC class C07A — Beta blockers
- tocilizumab — also decided by HAS in 2020Q3
- cabazitaxel — also decided by HAS in 2020Q3
- dibotermin alfa — also decided by HAS in 2020Q3
- vemurafenib — also decided by HAS in 2020Q3
Coverage: 14 decisions for propranolol from 6 agencies, 2007 to 2020. Data to 7 Sep 2026. ATC class C07A — Beta blockers. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.